The leadership team at Corium brings together industry-leading experts in drug development, manufacturing, and commercialization who are dedicated to doing more for our partners and patients.

Perry Sternberg, President and Chief Executive Officer

Perry SternbergPerry Sternberg, CEO of Corium, delivers a vision of a healthcare company that is patients' and caregivers' partner of choice. Based on an ethos of community and compassion, Corium strives to make a positive difference in the lives of others. As CEO, Perry focuses the company's efforts on the empowerment of patients, caregivers, and its employees.

According to Perry, every existing and potential relationship relies on the organic building of effective communication and trust, not one-sided messaging. Leading a healthcare business means being approachable, treating others with respect, and being open and eager to hear others' ideas. As Perry says, “Every person has something valuable and important to bring to the table when it comes to improving patient and caregiver outcomes.”

In his nearly 30 years of experience in the biopharmaceutical industry, Perry has overseen the launches of more than 20 products across a wide range of therapeutic areas in diverse markets. Under his leadership, Corium received FDA approval for and commercially launched 2 novel neuroscience therapies, AZSTARYS for the treatment of ADHD and ADLARITY for the treatment of Alzheimer's disease. Perry is passionate about, and thrilled by, the future that Corium is building for the people the company seeks to serve.

Perry spends his downtime with his wife, 3 children, and their family dog, and enjoys travel.

Jeremy Burchardt, Head of Technical Operations

Jeremy BurchardtJeremy Burchardt brings 25 years of experience in technical operations and manufacturing, with the last 20 years in the biopharmaceutical industry. As Corium’s Head of Technical Operations, Jeremy establishes the strategy and manages the end-to-end operations across supply chain, quality, and external manufacturing for both clinical and commercial programs. Prior to joining Corium in 2023, Jeremy served as Vice President of Supply Chain and Program Management for Corium’s contract development and manufacturing partner, Corium Innovations. Over the course of his tenure at Corium Innovations, he held positions of increasing responsibility in supply chain and program management, playing a critical role in moving several products from development to commercial launch. Jeremy holds a bachelor’s degree in Business Management and a master’s degree in Regulatory Affairs.

John Neeley, Chief Commercial Officer

John NeeleyJohn Neeley has more than 30 years of experience in the biotechnology and pharmaceutical industries, with commercial and government market experience across a wide range of therapeutic areas in global markets. Prior to joining Corium, John was with Shire Plc, where he served in various roles, most recently as the Head of Market Access and U.S. Pricing, and before that as Head of Global Market Access. During his 17+ years at Shire, he had responsibility for market access, U.S. government pricing and reporting, managed markets, government payor channels, and distribution. He has extensive product launch experience and has spearheaded several large-scale market access strategic initiatives that resulted in increased efficiency and multibillion-dollar cost savings. Before joining Shire, John was a managing partner and co-founder at Viking Healthcare Solutions, Inc. Prior to that, he spent time at Astra Pharmaceuticals and Boots Pharmaceuticals in various roles of increasing responsibility in managed markets, marketing, and sales. John holds a bachelor's degree in Business from Palm Beach Atlantic University and a Master of Business Administration from Florida Atlantic University.

Charles Oh, M.D., Chief Medical Officer

Charles OhDr. Charles Oh joined Corium in 2020 with more than 15 years of experience in the pharmaceutical/biotech industry. He has an established track record of industry accomplishments for achieving regulatory approval of multiple drugs and medical devices in North America and Europe, executing medical affairs strategies in support of commercial products, and leading scientific evaluations of business development opportunities. His industry experience encompasses a wide range of therapeutic areas, including pain management, cardiology, and neurology.

As chief medical officer at Corium, Charles drives the execution of clinical development programs, leads medical affairs to support commercial products, and builds the company's product pipeline. Prior to joining Corium, Charles served as Senior Vice President, Clinical Development at Acorda Therapeutics. Prior to that, he held roles of increasing responsibility and leadership at Johnson & Johnson and Purdue Pharma. Dr. Oh received his medical degree from Washington University in St. Louis and subsequently trained in internal medicine and cardiology. He also received an M.B.A. from the University of North Carolina at Chapel Hill and a B.S. in Biology from the University of Miami (FL).

Back to top